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Background:  We sought to evaluate the association between frailty and poor outcomes after TAVR using mortality and a novel definition 
of outcome that integrates quality of life with mortality in the PARTNER (Placement of Aortic Transcatheter Valve) trial.
methods:Patients who received TAVR at 1 of 3 high-enrolling sites where frailty was assessed systematically prior to TAVR were pooled. 
Gait speed, grip strength, serum albumin, and activities of daily living (ADLs) were used to derive a baseline frailty score. The cohort 
was dichotomized on the basis of median frailty score into frail and not frail groups. The impact of frailty on procedural outcomes, 1- year 
mortality, and poor outcome (defined as death, Kansas City Cardiomyopathy Questionnaire - Overall Summary Scale [KCCQ-OS] score 
<45, or ≥10- point decrease in KCCQ-OS score compared with baseline at 6 months) was evaluated.
results:Frailty status was assessed in 244 subjects who underwent TAVR (age 86 years, 52% male, STS score 10.9, gait speed 0.38 m/s, 
serum albumin 3.9 g/dL, grip strength 23.6 kg [men] and 12.2 kg [women], 172 (71%) independent in ADLs). There were no associations 
between frailty status and procedural outcomes (death, stroke, bleeding, vascular complications, pacemaker, and renal failure at 30 days). 
After adjusting for important clinical and demographic characteristics, frailty was independently associated with a 2.5-fold increased hazard 
of 1-year mortality after TAVR (95% CI 1.40-4.35, p=0.002). Poor outcome at 6-months after TAVR, using the combined mortality and 
quality of life endpoint, occurred in 41.9% of frail and 27.6% of non-frail participants (p=0.04). After multivariable adjustment, frailty was 
independently associated with increased odds of poor outcome after TAVR at 6 months (OR 2.21, 95% CI 1.09-4.46, p = 0.03).
conclusion:  Frailty as assessed by a composite of gait speed, grip strength, ADLs, and serum albumin is not associated with procedural 
outcomes, but is associated with increased 1-year mortality and a higher rate of poor outcome 6 months after TAVR.
